- Home
- Publications
- Publication Search
- Publication Details
Title
Analogs, formulations and derivatives of imatinib: a patent review
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 25, Issue 12, Pages 1411-1421
Publisher
Informa Healthcare
Online
2015-09-16
DOI
10.1517/13543776.2015.1089233
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epidemiology of chronic myeloid leukaemia: an update
- (2015) Martin Höglund et al. ANNALS OF HEMATOLOGY
- Variability in bioavailability of small molecular tyrosine kinase inhibitors
- (2015) Maikel Herbrink et al. CANCER TREATMENT REVIEWS
- Discoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discovery
- (2015) Sandeepkumar Kothiwale et al. DRUG DISCOVERY TODAY
- Half-dose gadoxetic acid-enhanced liver magnetic resonance imaging in patients at risk for nephrogenic systemic fibrosis
- (2015) Kyoung Doo Song et al. EUROPEAN JOURNAL OF RADIOLOGY
- Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?
- (2015) Morgan L Mace et al. EXPERT OPINION ON PHARMACOTHERAPY
- Chronic myeloid leukaemia
- (2015) Jane F Apperley LANCET
- CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans
- (2015) G. Eilers et al. MOLECULAR CANCER THERAPEUTICS
- Application of Nanotechnology in the Treatment and Diagnosis of Gastrointestinal Cancers: Review of Recent Patents
- (2015) Jose Prados et al. Recent Patents on Anti-Cancer Drug Discovery
- Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib
- (2014) C. Y. Cheah et al. BLOOD
- Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD
- (2013) A. Olivieri et al. BLOOD
- Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options
- (2013) Elias J. Jabbour et al. Clinical Lymphoma Myeloma & Leukemia
- The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib
- (2012) Benjamin J. Deadman et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- New Opportunities to Treat the T315I-Bcr-Abl Mutant in Chronic Myeloid Leukaemia: Tyrosine Kinase Inhibitors and Molecules that Act by Alternative Mechanisms
- (2010) S. Schenone et al. CURRENT MEDICINAL CHEMISTRY
- Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia
- (2010) Amber Fullmer et al. EXPERT OPINION ON PHARMACOTHERAPY
- Gastrointestinal stromal tumors: Current management
- (2010) Peter W.T. Pisters et al. JOURNAL OF SURGICAL ONCOLOGY
- Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2010) Wendy Stock LEUKEMIA & LYMPHOMA
- Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia
- (2010) E. I. Zimmerman et al. MOLECULAR PHARMACOLOGY
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
- (2009) Ronald P DeMatteo et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started